
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
The World Health Organization (WHO) first published guidance for national tuberculosis control programmes on managing tuberculosis in children (hereafter called "the Guidance") in 2006. The Guidance follows the principles of a public health approach aimed at optimizing outcomes, including the quality of life and survival, of children with tuberculosis; it also serves as a reference tool for countries to adopt and adapt according to their national circumstances. During 2009 and 2010, WHO updated the Guidance through a series of coordinated efforts to review and synthesize evidence on the correct dosages of antituberculosis medicines for use in children and the regimens that should be used for different manifestations of the disease in children. This evidence was assembled following systematic reviews, pharmacokinetic simulations and the preparation of evidence summaries, using GRADE profiles and analysis where appropriate. There have been major developments in advancing the use of new diagnostic tools, but these tools are not recommended for the diagnosis of latent tuberculosis infection or active tuberculosis disease in children. Preventive chemotherapy for children infected with the human immunodeficiency virus (HIV) will be addressed in other guidelines published by WHO. The availability of new evidence, specifically concerning the correct dosages of the four essential antituberculosis medicines, justified the rapid revision of WHO's Guidance. Representatives of the Stop TB Partnership's Childhood TB sub-working group who participated in the Guidelines Group formulated this revised guideline in the format of a Rapid Advice during a meeting of the Guidelines Group held in March 2010. In addition, two experts in paediatric pharmacology contributed to the development of this Rapid Advice.
This document provides rapid advice for the management of tuberculosis in children, updating previous World Health Organization guidance. The guidance follows a public health approach to optimize outcomes for children with tuberculosis, serving as a reference for national programs. It incorporates evidence from systematic reviews and pharmacokinetic simulations to determine correct dosages and treatment regimens for various manifestations of the disease in children. While diagnostic tools have advanced, they are not recommended for diagnosing latent or active tuberculosis in children, and preventive chemotherapy for HIV-infected children will be addressed in separate guidelines.
This rapid advice document is intended as a practical tool for healthcare professionals and policymakers involved in tuberculosis control programs for children. It synthesizes recent evidence to provide clear, actionable recommendations on treatment. The document's focus on public health principles aims to ensure that children with tuberculosis receive optimal care, improving both quality of life and survival rates. Its structure as a rapid advice guideline facilitates quick adoption and adaptation by national programs.
Page Count:
23
Publication Date:
2014-12-30
Publisher:
WHO Regional Office for the Western Pacific
ISBN-10:
9241500441
ISBN-13:
9789241500449
No comments yet. Be the first to share your thoughts!